ACE inhibitors or angiotensin receptor blockers may improve insulin sensitivity secondary to kinin, prostaglandins or nitric oxide accumulation, and increased peripheral blood flow to skeletal muscle.19 Thus, many studies have shown that blockers of the renin angiotensin system (ACE inhibitors and ARBs) reduce the risk of developing NOD when compared to placebo.28–31 In the present study, both ACE inhibitors and ARBs were found to have protective effects against developing NOD compared to placebo during antihypertensive therapy. The gene discussed is INS; the disease is dentatorubral-pallidoluysian atrophy.